AYLA

Ayala Pharmaceuticals Inc
0.503601
0.00 (0.00%)

Ayala Pharmaceuticals Inc. (AYLA) Fundamentals

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma-secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma-secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell-specific leukemia.
SHARE INFORMATION
Market Cap$ 7,463,733
Shares Outstanding14,820,727
Float5,966,876
Percent Float40.26%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 3,506,000
Latest Fiscal EPS$ -2.83
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions34
Institutional Holdings Date2022-12-31
Institutional Bought Previous 3 Months30,937
Institutional Holdings Percent18.0%
Institutional Sold Previous 3 Months15,657
Insider Holdings Date2022-12-31
Insider Bought Previous 3 Months-
Insider Holdings Percent2.7
Insider Sold Previous 3 Months-
Insider Shares Owned393,737
TRADING INFO
52 Week High$ 6.26
52 Week Low$ 0.36
52 Week High Change$ -90.88
21 Day Moving Average$ 0.4786
21 Day Extended Moving Average$ 0.496672
50 Day Moving Average$ 0.5147
50 Day Extended Moving Average$ 0.556008
200 Day Moving Average$ 1.2488
200 Day Extended Moving Average$ 1.8739
10 Day Average Volume30,738
20 Day Average Volume47,826
30 Day Average Volume45,669
50 Day Average Volume49,798
Alpha-0.100558
Beta1.9893
Standard Deviation0.236871
R20.208487
7 Day Price Change$ 0.00
7 Day Percent Change0.0%
21 Day Price Change$ 0.044
21 Day Percent Change9.57%
30 Day Price Change$ 0.1036
30 Day Percent Change25.9%
Month to Date Price Change$ 0.1035
Month to Date Percent Change25.87%
Quarter to Date Price Change$ 0.1035
Quarter to Date Percent Change25.87%
180 Day Price Change$ -0.9664
180 Day Percent Change-65.74%
200 Day Price Change$ -0.5764
200 Day Percent Change-53.37%
Year to Date Price Change$ 0.1035
Year to Date Percent Change25.87%

Ayala Pharmaceuticals Inc. (AYLA) Key Ratios

PROFITABILITY
EBIT Margin-2,166.3%
EBITDA Margin-2,157.7%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin5.2%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 587,000
Revenue Per Share$ 0.0396
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.90
Total Debt To Equity0.10
Int Coverage-89.80
Current Ratio2.30
Leverage Ratio1.40
Quick Ratio2.00
Long Term Debt To Capital0.05
VALUATION MEASURES
PE Ratio-0.20
Enterprise Value$ -3,335,282
Price to Sales12.715
Price to Free Cash-0.30
PE High Last 5 Years0.00
Price To Book0.90
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book0.90
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.70
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-128.24
Return on Equity-161.85
Return on Capital-158.88

Ayala Pharmaceuticals Inc. (AYLA) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorKost Forer Gabbay & Kasierer
CEOKenneth A. Berlin
Emplyoees35
Last AuditUE
CIK0001797336
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
AddressOppenheimer 4
Rehovot, 7670104
Websitehttps://www.ayalapharma.com
Facsimile-
Telephone+972 8574440553
Email-


Your Recent History
NASDAQ
AYLA
Ayala Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.